Unavailable
Unavailable
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/19/2023 | $89.00 | Neutral → Buy | CL King |
3/11/2022 | $9.00 → $8.00 | Outperform | RBC Capital |
12/20/2021 | $8.50 → $9.00 | Outperform | RBC Capital |
"Looking forward, we believe sales volumes will continue to gradually improve due to ongoing recovery in Rigid Polyols and growth in Surfactant volumes including the expected recovery of the Agricultural business in the second half of the year," said Scott Behrens, President and Chief Executive Officer.
Stepan (NYSE:SCL) reported quarterly Adj earnings of $0.64 per share which beat the analyst consensus estimate of $0.35 by 82.86 percent. This is a 9.86 percent decrease over earnings of $0.71 per share from the same period last year. The company reported quarterly sales of $551.418 million which missed the analyst consensus estimate of $575.825 million by 4.24 percent. This is a 15.35 percent decrease over sales of $651.436 million the same period last year.
NORTHBROOK, Ill., July 31, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: Second Quarter 2024 Highlights Reported net income was $9.5 million, down 25% versus prior year. Adjusted net income(1) was $9.4 million, down 22% versus prior year, largely due to a higher effective tax rate in 2024.Pre-tax earnings were negatively impacted by $18.9 million due to higher operating costs at our Millsdale site, primarily related to a flood event ($11.8 million), pre-commissioning expenses at our new Alkoxylation investment in Pasadena, Texas ($3.6 million) and expenses rel
NORTHBROOK, Ill., July 31, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has declared a quarterly cash dividend on the Company's common stock of $0.375 per share. The dividend is payable on September 13, 2024, to common stockholders of record on August 30, 2024. The Company increased its quarterly cash dividend in the fourth quarter of 2023 by $0.010 per share, marking the 56th consecutive year that the Company has increased its cash dividend to stockholders. Corporate Profile Stepan Company is a major manufacturer of s
NORTHBROOK, Ill., July 10, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) will issue its second quarter 2024 earnings results on Wednesday, July 31, 2024 at approximately 7:00 a.m. ET (6:00 a.m. CT). Supporting slides will be posted at approximately the same time on the Investors/Presentations page at www.stepan.com. The Company will hold a conference call to discuss and answer questions about its financial and operational performance on the same day at 9:00 a.m. ET (8:00 a.m. CT). The call will be hosted by Scott R. Behrens, President and Chief Executive Officer, and Luis E.
4 - STEPAN CO (0000094049) (Issuer)
4 - STEPAN CO (0000094049) (Issuer)
4 - STEPAN CO (0000094049) (Issuer)
NORTHBROOK, Ill., July 31, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: Second Quarter 2024 Highlights Reported net income was $9.5 million, down 25% versus prior year. Adjusted net income(1) was $9.4 million, down 22% versus prior year, largely due to a higher effective tax rate in 2024.Pre-tax earnings were negatively impacted by $18.9 million due to higher operating costs at our Millsdale site, primarily related to a flood event ($11.8 million), pre-commissioning expenses at our new Alkoxylation investment in Pasadena, Texas ($3.6 million) and expenses rel
NORTHBROOK, Ill., July 31, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has declared a quarterly cash dividend on the Company's common stock of $0.375 per share. The dividend is payable on September 13, 2024, to common stockholders of record on August 30, 2024. The Company increased its quarterly cash dividend in the fourth quarter of 2023 by $0.010 per share, marking the 56th consecutive year that the Company has increased its cash dividend to stockholders. Corporate Profile Stepan Company is a major manufacturer of s
NORTHBROOK, Ill., July 10, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) will issue its second quarter 2024 earnings results on Wednesday, July 31, 2024 at approximately 7:00 a.m. ET (6:00 a.m. CT). Supporting slides will be posted at approximately the same time on the Investors/Presentations page at www.stepan.com. The Company will hold a conference call to discuss and answer questions about its financial and operational performance on the same day at 9:00 a.m. ET (8:00 a.m. CT). The call will be hosted by Scott R. Behrens, President and Chief Executive Officer, and Luis E.
SC 13G - STEPAN CO (0000094049) (Subject)
SC 13G/A - STEPAN CO (0000094049) (Subject)
SC 13G/A - STEPAN CO (0000094049) (Subject)
8-K - STEPAN CO (0000094049) (Filer)
10-Q - STEPAN CO (0000094049) (Filer)
8-K - STEPAN CO (0000094049) (Filer)
4 - STEPAN CO (0000094049) (Issuer)
CL King upgraded Stepan Company from Neutral to Buy and set a new price target of $89.00
RBC Capital reiterated coverage of Shawcor with a rating of Outperform and set a new price target of $8.00 from $9.00 previously
RBC Capital reiterated coverage of Shawcor with a rating of Outperform and set a new price target of $9.00 from $8.50 previously
NORTHBROOK, Ill., Feb. 15, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) announced today the appointment of Susan M. Lewis as a Director of Stepan, effective on February 15, 2024. Ms. Lewis spent over 30 years at Dow Inc., a materials science company, and was part of the management team of Corteva, Inc., a global agriculture company, following its spinoff from DowDuPont Inc. Ms. Lewis served as Senior Vice President, Global Operations of Corteva from 2018 until her retirement in 2021, after which she worked as a business and executive consultant through 2023. Ms. Lewis held senior management roles with operations, sustainability and risk management responsibilities and led organizational r
VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an
NORTHFIELD, Ill., Jan. 27, 2021 /PRNewswire/ -- Stepan Company (NYSE: SCL) today announced the appointment of Lorinda Burgess as a director of the Company, effective on January 27, 2021. Ms. Burgess currently serves as Vice President, Finance and Chief Financial Officer, Americas Region of Medtronic Inc. In her over 20-year career with Medtronic, Ms. Burgess has held multiple financial leadership positions covering a range of geographies. Prior to joining Medtronic, Ms. Burgess held key finance and investor relations positions with Marshall Field's Corporation and BET Holdings Inc. Ms. Burgess earned a BA in Political Science from the University of Michigan, and an MBA from The Ohio State